Artikel ; Online: Prospective observational registry of perioperative and periprocedural management of antithrombotic therapy in "real world": the REQXAA study.
Revista espanola de cardiologia (English ed.)
2023 Band 76, Heft 9, Seite(n) 729–738
Abstract: Introduction and objectives: There is scarce real-world evidence on the management of perioperative antithrombotic treatment according to current recommendations. The aim of this study was to analyze the management of antithrombotic treatment in ... ...
| Abstract | Introduction and objectives: There is scarce real-world evidence on the management of perioperative antithrombotic treatment according to current recommendations. The aim of this study was to analyze the management of antithrombotic treatment in patients undergoing surgery or another invasive intervention and to assess the consequences of this management on the occurrence thrombotic or bleeding events. Methods: This prospective, observational, multicenter and multispecialty study analyzed patients receiving antithrombotic therapy who underwent surgery or another invasive intervention. The primary endpoint was defined as the incidence of adverse (thrombotic and/or hemorrhagic) events after 30 days of follow-up with respect to management of perioperative antithrombotic drugs. Results: We included 1266 patients (male: 63.5%; mean age 72.6 years). Nearly half of the patients (48.6%) were under chronic anticoagulation therapy (mainly for atrial fibrillation; CHA Conclusions: The implementation of recommendations on the perioperative/periprocedural management of antithrombotic therapy in real-world patients is poor. Inappropriate management of antithrombotic treatment is associated with an increase in both thrombotic and hemorrhagic events. |
|---|---|
| Mesh-Begriff(e) | Humans ; Male ; Aged ; Anticoagulants/therapeutic use ; Fibrinolytic Agents/therapeutic use ; Fibrinolytic Agents/adverse effects ; Prospective Studies ; Hemorrhage/chemically induced ; Hemorrhage/epidemiology ; Hemorrhage/complications ; Risk Factors ; Atrial Fibrillation/complications ; Atrial Fibrillation/drug therapy ; Registries ; Platelet Aggregation Inhibitors/adverse effects |
| Chemische Substanzen | Anticoagulants ; Fibrinolytic Agents ; Platelet Aggregation Inhibitors |
| Sprache | Spanisch |
| Erscheinungsdatum | 2023-03-11 |
| Erscheinungsland | Spain |
| Dokumenttyp | Observational Study ; Multicenter Study ; Journal Article |
| ZDB-ID | 2592481-3 |
| ISSN | 1885-5857 ; 1885-5857 |
| ISSN (online) | 1885-5857 |
| ISSN | 1885-5857 |
| DOI | 10.1016/j.rec.2023.03.003 |
| Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Volltext online
Zusatzmaterialien
Kategorien
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.